K
19.78
0.18 (0.92%)
| Previous Close | 19.60 |
| Open | 19.74 |
| Volume | 236,919 |
| Avg. Volume (3M) | 322,063 |
| Market Cap | 1,428,147,712 |
| Price / Sales | 3.85 |
| Price / Book | 3.35 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2024 |
| Profit Margin | -2.36% |
| Operating Margin (TTM) | -8.61% |
| Diluted EPS (TTM) | -0.120 |
| Quarterly Revenue Growth (YOY) | 67.40% |
| Total Debt/Equity (MRQ) | 2.42% |
| Current Ratio (MRQ) | 3.24 |
| Operating Cash Flow (TTM) | 11.24 M |
| Levered Free Cash Flow (TTM) | 25.74 M |
| Return on Assets (TTM) | -3.16% |
| Return on Equity (TTM) | -2.15% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Kiniksa Pharmaceuticals, Ltd. | Bullish | Bullish |
AIStockmoo Score
1.4
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -4.0 |
| Average | 1.38 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 4.10% |
| % Held by Institutions | 97.97% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (JP Morgan, 102.22%) | Buy |
| Median | 37.50 (89.59%) | |
| Low | 35.00 (Evercore ISI Group, 76.95%) | Buy |
| Average | 37.50 (89.59%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 22.52 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 05 Nov 2024 | 40.00 (102.22%) | Buy | 22.03 |
| Evercore ISI Group | 30 Oct 2024 | 35.00 (76.95%) | Buy | 23.01 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Jan 2025 | Announcement | Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance |
| 06 Jan 2025 | Announcement | Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference |
| 26 Nov 2024 | Announcement | Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference |
| 12 Nov 2024 | Announcement | Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference |
| 29 Oct 2024 | Announcement | Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution |
| 28 Oct 2024 | Announcement | Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis |
| 22 Oct 2024 | Announcement | Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |